[1] Arimura A, et al. Pituitary adenylate cyclase - activating polypeptide (PACAP) and its receptor. Front Neuroendocrinol. 1992 Jul;13(3):259 - 308. [2] Vaudry H, et al. Pituitary adenylate cyclase - ...

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” ...

A new study published in Mycology highlights the alarming evolutionary rate of Sporothrix, the fungus that causes ...

As of 2:53:36 PM EDT. Market Open. Loading Chart for CYCN ...

A novel therapeutic showed significant promise in slowing aortic valve calcification, potentially extending time until or eliminating need for transcatheter or surgical intervention for stenosis, ...

An expert in connective tissue disease–associated interstitial lung disease described best approaches for rheumatologists to be proactive in screening, diagnosing, treating, and monitoring patients.

MM 419447，一种利那洛肽代谢物，是一种鸟苷酸环化酶 C (guanylate cyclase-C) 激动剂。MM 419447 可被用作研究便秘型肠易激综合征 (IBS-C)。 调节作用：多肽通常可以调节人体内部环境，平衡内分泌，促进生长激素分泌等7。 免疫作用：多肽可能作为免疫佐剂，增强免疫 ...

Safety of use during pregnancy or breastfeeding is uncertain. These drugs also act to increase intestinal fluid and intestinal movement by targeting receptors called guanylate cyclase-C (GC-C) ...

This process is similar to the PDE5 inhibitors, so these two medicine classes aren't taken together. Adempas (riociguat) is the only drug in its class of soluble guanylate cyclase (sGC) stimulators.

After a quiet few years Merck has returned to the category with soluble guanylate cyclase (sGC) stimulators Adempas (riociguat) and Verquvo (vericiguat) – partnered with Bayer – for PAH and ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the ...